Treeway TW001 B.V.;Sytske Hyke MOOLENAAR;Ronald VAN DER GEEST
发明人:
Sytske Hyke MOOLENAAR,Ronald VAN DER GEEST
申请号：
IL27183620
公开号：
IL271836D0
申请日:
2020.01.05
申请国别(地区):
IL
年份:
2020
代理人:
摘要：
The present invention relates to the use of a liquid aqueous solution of edaravone in the treatment of an oxidative stress-mediated neurodegenerative disorder in a human patient, said treatment comprising at least once daily oral administration of the liquid edaravone solution to the human patient, to provide a daily dose of 40-120 mg edaravone during an uninterrupted period of at least 10 days. Examples of oxidative stress-mediated neurodegenerative disorders that can be treated in this way include amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), cerebral amyloid angiopathy (CAA), Alzheimer's disease and Parkinson's disease.
